

30 July 2024

TechKnow Invest Roadshow presentation

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the **Company**') (ASX: TRI) is pleased to advise that Chief Operating Officer, Mr Kai Sun will be presenting at the TechKnow Invest Roadshow event in Sydney and Melbourne on 30 July 2024 and 31 July respectively. For investors that cannot attend in-person, livestream links are available below.

Sydney (presentation commencing at 10:15am AEST):

<https://www.youtube.com/live/N3p-ElbxNjc>

Melbourne (presentation commencing at 1:45pm AEST):

<https://www.youtube.com/live/MEp9AI72Rdc>

A copy of the Company's presentation is attached to this announcement.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au



AI-driven solutions to objectively screen for mental health conditions

TECHKNOW INVEST ROADSHOW – JULY 2024

(ASX: TRI)

This presentation has been authorised for release by the Board of TrivarX Limited

Forward looking statements

The purpose of the presentation is to provide an update of the business of TrivarX Limited (ASX: TRI). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by TrivarX Limited and should not be relied upon as an independent source of information. Please contact TrivarX Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of TrivarX Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, complete-ness or reliability of the information, or the likelihood of fulfilment of any forward-looking statement or any out-comes expressed or implied in any forward-looking statements.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside TrivarX Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Actual results could differ materially to the assumptions made and TrivarX Limited's current intentions, plans, expectations and beliefs about the future. You are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.


This presentation should not be relied on as a recommendation or forecast by TrivarX Limited. This presentation does not constitute investment advice or should be construed as either an offer to sell, or a solicitation of an offer, to buy or sell shares in any jurisdiction.

Corporate overview

Corporate Snapshot	ASX code:	TRI
	Shares on issue:	~457m
	Market capitalisation (at \$0.036 per share): (as at 29 July 2024)	~A\$16.5m
	Options on issue:	~172.8m
	Debt:	Nil

Major shareholders	FIL Investment Management (Hong Kong) Limited	9.30%
	Top 20:	45.72%

Board and management	Non-Executive Chairman	Mr David Trimboli
	Chief Operating Officer	Mr Kai Sun
	Executive Director	Dr Tony Keating
	Non-Executive Director	Mr Chris Ntoumenopoulos
	Chief Medical Officer	Dr Archie Defillo
	Head of Artificial Intelligence	Mr Massimiliano Grassi



Company overview

Pioneering the use of AI to aid in the early detection of mental health conditions



AI-driven, scientifically-backed software tools to objectively screen mental health conditions



Lead program, MEB-001 uses biometric data, EEG and ECG recordings collected during sleep studies to screen for current Major Depressive Episode




Phase 2 Study successfully completed across 15 US-based sleep centres. Final analysis reported sensitivity of 87% and specificity of 72%



Defined pathway to US FDA regulatory approval via De Novo submission – Company has held multiple pre-submission meetings with the US FDA and gained positive feedback to date



The world's largest database of sleep study data labelled with patient's mental health status – a strong foundation for algorithm development in other mental health conditions



Unique opportunity to deploy into solution sleep centres, where there is a high prevalence of undiagnosed depression – but no screening currently performed

The US mental health epidemic

- ▶ 21% of US adults experience mental illness – the equivalent to over 50m Americansⁱ
- ▶ 1 in 25 US adults live with a serious mental health condition such as major depression, bipolar and schizophreniaⁱⁱ
- ▶ 55% of US adults with a mental health condition receive no treatmentⁱⁱⁱ
- ▶ Mental health misdiagnosis is rife – Major Depressive Disorder: 65.9%, Social anxiety: 97.8%, Bipolar: 92.7%^{iv}



Prevalent mental health illnesses

ⁱ <https://mhanational.org/issues/state-mental-health-America>
ⁱⁱ <https://www.cdc.gov/mentalhealth>
ⁱⁱⁱ <https://mhanational.org/issues/state-mental-health-America>
^{iv} <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184591/>

Sleep and mental health are deeply intertwined

TrivarX is exploring the robust relationship between sleep and mental health using AI

- ▶ Depression and sleep problems are closely linked:
 - People with insomnia may have a tenfold higher risk of developing depression than people who get a good night sleep
 - Among people with depression, '75% of people have trouble falling or staying asleep'

- ▶ MEB-001 uses biometric data, EEG, and ECG recordings collected during sleep studies to screen for current Major Depressive Episode (cMDE)



¹ <https://www.hopkinsmedicine.org/health/wellness-and-prevention/depression-and-sleep-understanding-the-connection>

A scientifically backed approach

Underpinned by leading management, extensive experience and industry validation

Extensive industry validation

- ▶ Since the early 2000s, TRI's dedicated scientific personnel have built evidence to support that EEG and ECG data collected during sleep can be used to assist with the screening of mental health conditions via AI
- ▶ Three peer reviewed publications and top congress scientific presentations
- ▶ Four clinical trials completed including a Phase 2 clinical trial for current Major Depressive Episode (cMDE)

Leading scientific expertise



Archie Defillo M.D. – Chief Medical Officer


- ▶ 25 years clinical experience with neurological diseases and a trained neurosurgeon
- ▶ 70+ publications on topics predominantly based on heart rate studies
- ▶ Dedicated to advancing TRI's knowledge of heart rate variability and autonomic modulation



Massimilano Grassi PhD – Head of AI

- ▶ 15 years experience as a data scientist in mental health field with an extensive background in psychology
- ▶ Ph. D in Supervised Machine Learning for Clinical Psychiatry
- ▶ Focused on the development of machine learning algorithms using sleep as the window into mental health

AI used to connect proprietary sleep biomarkers with mental health



An enviable global database

Leveraging the world's largest repositories of EEG and ECG data combined with neuropsychiatric evaluations

Over 1,000 unique patient cases collected

1,000+ PHQ9s completed by patients

Over 400 MINIs

Used by clinicians in structured interviews to find cases of MDE, Manic and Hypomanic episodes (Bipolar Disorder), Panic Disorder, OCD, PTSD, psychotic and mood disorders, General anxiety Disorder and medically related associated disorders

MEB-001, TrivarX's lead product targets the major market of depression

- ▶ Kaiser Permanente estimates that doctors miss 50% of depression cases in the USⁱ
- ▶ Only 1.4% of US outpatients are screened for depression at the primary care levelⁱⁱ
- ▶ Depression screening is not part of clinical practice in sleep clinics in the US or globallyⁱⁱⁱ
- ▶ 21% of people undergoing a sleep study have depression^{iv}

ⁱ <https://www.ncbi.nlm.nih.gov/books/NBK592805/>

ⁱⁱ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673056/>

ⁱⁱⁱ <https://jcsn.aasm.org/doi/10.5664/jcsn.10398>

^{iv} <https://pubmed.ncbi.nlm.nih.gov/36644846/>

MEB-001 is the only objective depression screening tool for sleep centres

MEB-001 is TRI's AI-driven algorithm which assists in the screening of depression

MEB-001 uses AI to identify depression from EEG and ECG data collected during a sleep study

Clinical and regulatory development well progressed


- ▶ TrivarX's first proprietary algorithm, MEB-001, is being developed as a tool to be used to screen and aid in the diagnosis of current Major Depressive Episode (cMDE)
- ▶ Regulatory approval is well advanced – Phase 2 clinical study completed and multiple pre-submission meetings with US FDA
- ▶ Pivotal study set to commence December 2024 with De Novo submission to FDA anticipated [early H2 CY2025]

Positive outcome in MEB-001 Phase 2 trial

Summary			
Study	Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) – NCT0570822		
Objective	Use MEB-001 to detect likelihood of a current Major Depressive Episode (cMDE) using Clinician Reporting Outcomes (CRO) assessment in individuals referred to a sleep clinic		
Sites	15 sleep centres across Florida, Minnesota, North Carolina, South Carolina, Ohio and Texas		
Subjects	400 patients aged between 22 and 75 years old who have been referred to a sleep clinic		
Reference standard	Current Major Depressive Episode (cMDE) identified by MINI administered by clinician		
Results			
Sensitivity	Specificity	Positive Predicative Value (PPV)	Negative Predicative Value (NPV)
87% (95% CI 73-95%)	72% (95% CI 66-77%)	35% (95% CI 27-45%)	97% (95% CI 93-99%)
The ability for the test to correctly identify patients with the disease	The ability of the test to correctly identify patients without the disease	The likelihood that an individual with a positive test truly has the disease	The likelihood that an individual with a negative test truly does not have the disease

The start of a large global opportunity in mental health

Trivarx is positioned to be the world leader in AI-based assessment of mental health



Multiple near-term value catalysts

Catalyst	Timeframe (CY)	Status
Second FDA Pre-Submission Meeting	H1 2024	✓
Completion of MEB-001 SAMDE Phase 2 Trial	H1 2024	✓
Final data from MEB-001 SAMDE Phase 2 Trial	H2 2024	✓
Appointments to strengthen Board of Directors	H2 2024	✓
Commencement and completion of pivotal study design	H2 2024	
Third FDA Pre-Submission Meeting to confirm MEB-001 Pivotal design	H2 2024	
CRO appointment for MEB-001 Pivotal study	H2 2024	
IRB approval for MEB-001 Pivotal study	H2 2024	
Establish Scientific Advisory Board ahead of US FDA submission	H2 2024	
Additional Board appointments to strengthen US presence	H2 2024	
Commencement of FDA registration MEB-001 Pivotal Trial	H2 2024	
Completion of MEB-001 cMDE Pivotal Trial and interim results	H1 2025	
Submission of MEB-001 De Novo application to US FDA	H2 2025	



CONTACT

TrivarX Limited (ASX: TRI)
E: Investors@trivarx.com
A: 647 Beaufort Street, Mt Lawley, WA 6050

Kai Sun – Chief Operating Officer:
T: +61 433 549 602
E: Kai.sun@trivarx.com

Henry Jordan – Six Degrees Investor Relations
T: +61 431 271 538
E: Henry.Jordan@sdir.com.au

Appendix 1: Intellectual Property and patents

Four patents granted and currently active

1

US Pat. No. 10,912,508
Issued 09 Feb 2021

Method and system for assessing
mental state

2

US Pat. No. 10,638,965
Issued 05 May 2020

Method and system for monitoring
stress conditions

3

US Pat. No. 10,039,485
Issued 07 Aug 2018

Method and system for assessing
mental state

4

US Pat. No. 9,861,308
Issued 09 Jan 2018

Method and system for monitoring
stress conditions

Appendix 2: Clinical research and technology

Supervised Artificial Intelligence

Data has been taken from 400+ subjects to date:

- ▶ Prospective data collection – remains ongoing
- ▶ Combining EEG and ECG enables the technology to map the connectivity between brain and heart activity throughout sleep stages
- ▶ TRI has identified novel sleep biomarkers that map a person's mood disorder

Clinical Study	SLEEP	SADB	SAMDE PI	SAMDE PII	Clinical Validation
Status	Complete	Complete	Complete	Complete	Planned
Software Module(s)	SEEG SHR V	SEEG SHR V	SEEG SHR V DMI	SEEG SHR V DMI	SEEG SHR V DMI
Location	USA	USA	USA	USA	USA
Study Size	40	329	313	Up to 400	TBD
Study Dates	2019	2019	2021	2023	2024 (Planned Study Start)
Subjective Data	None	BDI PHQ-9	MINI (PRO) PHQ-9	MINI (CRO) PHQ-9	MINI (CRO) PHQ-9
Value Delivered	Internal POC for Supervised AI	Early AI performance data vs. PRO	Enhanced PRO w/reduced noise and broadened symptoms	Use of MINI (CRO) as proposed ground truth	US FDA clearance
Objective Data	EEG ECG	EEG ECG	EEG ECG Socio-demographics	EEG ECG Socio-demographics	EEG ECG Socio-demographics Risk Factors
Hardware	In-Lab Polysomnography				
Focus	Autonomic Function	Depressive Symptoms/Severity			Depressive Symptoms/Severity

Appendix 3: MEB-001 Hypnogram outputs

cMDE Negative

cMDE Positive

